Repligen Earnings Preview

After beating estimates last quarter, Repligen (Nasdaq: RGEN  ) has set the standard for itself. The company will unveil its latest earnings on Thursday, June 9. A biopharmaceutical company, Repligen is focused primarily on the development of novel therapeutics for radiology and neuropsychiatry.

What analysts say:

• Buy, sell or hold?: The lone analyst following Repligen rates it a hold, suggesting that investors should stand pat. Analysts like larger competitor Life Technologies overall, with 13 out of 17 analysts rating Life Technologies a buy.
• Revenue Forecasts: On average, analysts predict $6.2 million in revenue this quarter. That would represent a rise of 27.3% from the year-ago quarter.
• Wall St. Earnings Expectations: The lone analyst is estimating a loss of 3 cents per share.

What our community says:
CAPS All Stars are solidly behind the stock with 100% giving it an "outperform" rating. The community at large agrees with the All Stars -- 98.3% awarded it a rating of "outperform." Fools are bullish on Repligen and haven't been shy with their opinions lately, logging 107 posts in past 30 days. Repligen's CAPS rating -- five out of five stars -- indicates a bullish sentiment for the stock.

Management:
Revenue has now gone up for three straight quarters. In third quarter of the last fiscal year, revenue rose 34.8% to $7.1 million. The figure rose 38.5% in second quarter from the year earlier.

Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross and net margins over the past four quarters.  

Quarter	Q3	Q2	Q1	Q4
Gross Margin	73.7%	74.7%	76.6%	74.7%
Net Margin	5.3%	8.5%	14.1%	-33.4%

One final thing: If you'd like more analysis on the company, make sure to follow its moves by adding Repligen to your watchlist.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.